NCT00814788View on ClinicalTrials.gov

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Bicalutamide

50 mg oral tablet daily

DRUG

Everolimus

10 mg oral capsule daily

Trial Locations (1)

95817

University of California Davis Cancer Center, Sacramento

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, Davis

OTHER

NCT00814788 - Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter